Document text
Principal Investigator: Jayanth Panyam
Organization: TEMPLE UNIV OF THE COMMONWEALTH
Fiscal Year: 2022
Award: $352,261
Funding agency: National Cancer Institute
Agonists of toll like receptors (TLRs) are promising anticancer vaccine adjuvants because of their ability to
induce proinflammatory cytokines necessary to generate a robust immune response. However, currently available
TLR agonists suffer from a number of limitations including self-regulatory immunosuppression and unfavorable
local pharmacokinetics resulting in poor availability within dendritic cells. Further, current TLR agonist-based
anticancer vaccines generate a robust cytotoxic CD8 T cell response but not CD4 Th 1 helper T cell response,
which is critical for inducing effective, long-term antitumor immunity. We will address these important challenges
through a synergistic combination of drug discovery and drug delivery efforts. Our team has developed a suite
of highly substituted imidazoquinolines, which activate TLR7 and/or 8 and induce significantly higher levels of
cytokines compared to imiquimod, an FDA approved TLR7 agonist. Our studies show the balance between proinflammatory
and immunosuppressive cytokines can be tuned through structural modifications. Encapsulation of
these novel agonists in acidic pH responsive nanoparticles (NPs) resulted in robust activation of CD4 and COB
T cells as well as natural killer (NK) cells, leading to a stronger anticancer immune response than free agonist
or that encapsulated in non-pH responsive NPs. Importantly, intradermal delivery of NP vaccine using a hollow
microneedle platform led to an enhanced Th1 immune response, which is essential for effective induction of
long-term antitumor immunity. We will build on these exciting findings and further optimize the new agonists for
efficient encapsulation in pH responsive NPs, tune the NP properties for improved targeting of dendritic cells
following delivery via hollow microneedles, and investigate potentiation of NK cell-mediated antibody-mediated
cellular cytotoxicity. The Specific Aims of this revised R01 grant application include:
Aim 1: Design and synthesize TLR7/8 agonists that are optimized for NP encapsulation
Aim 2: Optimize pH responsive NP formulation for hollow microneedle-assisted ID delivery
Aim 3: Determine anticancer efficacy of NP vaccine following hollow microneedle-assisted ID delivery
We expect our studies will identify new design principles and delivery strategies for TLR agonists that overcome
the limitations of current anticancer vaccines and further advance the field of cancer immunotherapy.
Terms: <Ab-dependent cellular cytotoxicity><Address><Agonist><Aldara><Antibodies><Antigens><Applications Grants><Assay><BCG immunotherapy><BCG therapy><BCG treatment><Bacillus Calmette Guérin immunotherapy><Bacillus Calmette Guérin therapy><Bacillus Calmette-Guerin Immunotherapy><Bacillus Calmette-Guerin Therapy><Basal Cell Epithelioma><Basal cell carcinoma><Basiloma><Bioassay><Biologic Assays><Biological Assay><Bladder Cancer><Breast Cancer><Breast Cancer Model><Breast tumor model><CSIF><CSIF-10><Cancers><Cell Body><Cell surface><Cell-Mediated Lympholytic Cells><Cells><Characteristics><Charge><Chemosensitization><Chemosensitization/Potentiation><Combined Modality Therapy><Common Rat Strains><Cytokine Synthesis Inhibitory Factor><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><Cytotoxic cell><Dendritic Cells><Drug Combinations><Drug Delivery><Drug Delivery Systems><Drug Kinetics><Drug Precursors><EGF Receptor><EGFR><ELISA><ERBB Protein><ERBB2><ERBB2 gene><Encapsulated><Enzyme-Linked Immunosorbent Assay><Epidermal Growth Factor Receptor><Epidermal Growth Factor Receptor Kinase><Epidermal Growth Factor Receptor Protein-Tyrosine Kinase><Epidermal Growth Factor-Urogastrone Receptors><Equilibrium><FDA approved><Formulation><Grant Proposals><HER -2><HER-2><HER1><HER2><HER2 Genes><HER2/neu><HPV><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Human><Human Papilloma Virus><Human Papillomavirus><IL-10><IL10><IL10A><Imiquimod><Immune><Immune response><Immunes><Immunological response><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Inducer Cells><Inducer T-Lymphocytes><Infectious Human Wart Virus><Infiltration><Inflammatory><Injections><Interleukin 10 Precursor><Interleukin-10><Investigation><K lymphocyte><Lead><Ligands><Lipid A><Malignant Bladder Neoplasm><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Bladder><Malignant neoplasm of urinary bladder><Mediating><Modeling><Modern Man><Modification><Multimodal Therapy><Multimodal Treatment><Myeloid-derived suppressor cells><NEU Oncogene><NEU protein><NK Cells><Natural Killer Cells><Oncogene ErbB2><Ovalbumin><PBMC><Particle Size><Pb element><Peripheral Blood Mononuclear Cell><Pharmacokinetics><Potentiation><Pro-Drugs><Prodrugs><Property><Rat><Rats Mammals><Rattus><Regulatory T-Lymphocyte><Rodent Ulcer><Safety><Series><Site><Specificity><Surface><System><T cell response><T-Cells><T-Lymphocyte><TGF-alpha Receptor><TKR1><TLR protein><TLR7><TLR7 gene><Techniques><Toll-Like Receptor 7><Toll-Like Receptor Family Gene><Toll-like receptors><Transforming Growth Factor alpha Receptor><Treg><Tumor Immunity><Up-Regulation><Upregulation><Urinary Bladder Cancer><Urinary Bladder Malignant Tumor><Urogastrone Receptor><Vaccination><Vaccine Adjuvant><Vaccines><Veiled Cells><Viscosity><analog><anti-cancer><anti-cancer immunotherapy><anti-tumor immunity><antibody dependent cell mediated cytotoxicity><antibody dependent cytotoxicity><antibody mediated cellular cytotoxicity><antibody-dependent cell cytotoxicity><antibody-dependent cellular cytotoxicity><antibody-mediated cytotoxicity><anticancer><anticancer immunotherapy><antigen-specific T cells><antitumor immunity><balance><balance function><base><c-erbB-1><c-erbB-1 Protein><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><cancer immunity><cancer immunotherapy><cancer type><combination therapy><combined modality treatment><combined treatment><cytokine><cytotoxic><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><design><designing><draining lymph node><drug discovery><enzyme linked immunoassay><erbB-1><erbB-1 Proto-Oncogene Protein><erbB-2 Genes><erbBl><heavy metal Pb><heavy metal lead><herstatin><host response><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune-based cancer therapies><immunogen><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive myeloid cells><immunotherapy for cancer><immunotherapy of cancer><immunotoxicity><improved><intravesical BCG><killer T cell><malignancy><malignant breast neoplasm><malignant breast tumor><mammary cancer model><mammary tumor model><multi-modal therapy><multi-modal treatment><myeloid suppressor cells><myeloid-derived suppressive cells><nano particle><nano particle delivery><nano vaccine><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><nanovaccine><neoplasm/cancer><neu Genes><novel><proto-oncogene protein c-erbB-1><regional lymph node><regulatory T-cells><response><small molecule><suppressive myeloid cells><systemic toxicity><thymus derived lymphocyte><toxic reaction in immunology><trafficking><tumor><wart virus>